Pharmaceuticals Market Research Reports & Industry Analysis

Pharmaceuticals refer to compounds manufactured for use as a medicinal drug. Companies active in the pharmaceutical industry are involved in development, production and marketing of pharmaceuticals.

The global market for pharmaceuticals is demonstrating a substantial growth in Latin America and Asia, but is relatively stable in Europe. The worldwide market is assessed at about USD 300 billion yearly. The USA, Japan, Germany, France and China are the top pharmaceutical markets. The pharmaceutical industry benefits from the ageing population; new medical discoveries and new drugs approvals; the increased number of chronic, degenerative and heart diseases, and cancer.

The research reports of this Catalogue cover all the major categories within global, regional and local pharmaceuticals markets. The reports offer overviews of the market trends, drivers; factors contributing to market growth. The challenges faced by industry participants, analyses of the top companies involved in the marketplace, and the key market news are provided in the reports.

Found 15351 publications
Global Varicella Vaccine Industry 2014 Market Research Report US$ 2,850.00

2014 Global Varicella Vaccine Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Varicella Vaccine industry, focusing on the main regions (North America, Europe and Asia) and the main countries ( ...

Dec, 2014 176 pages
Global Pharmaceutical Glass Industry 2014 Market Research Report US$ 2,850.00

2014 Global Pharmaceutical Glass Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Pharmaceutical ... America, Europe and Asia) and the main countries (United States, Germany, Japan and China). The report firstly introduced the Pharmaceutical ...

Dec, 2014 176 pages
Global Hepatitis B Vaccine Industry 2014 Market Research Report US$ 2,850.00

2014 Global Hepatitis B Vaccine Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Hepatitis B Vaccine industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and ...

Dec, 2014 176 pages
Global Animal Vaccine Industry 2014 Market Research Report US$ 2,850.00

2014 Global Animal Vaccine Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Animal ... , Germany, Japan and China). The report firstly introduced the Animal Vaccine basics: definitions, classifications, applications and industry chain overview; ...

Dec, 2014 176 pages
Zanamivir - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... , save searches and results This report covers: International Nonproprietary Name: Zanamivir indications: Treatment or prophylaxis of infections due to Influenza A or B viruses innovator: Glaxosmithkline (Relenza) Country Coverage: Australia Canada France Germany Great Britain Italy Japan ...

Jan, 2015
Vorapaxar - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... This report covers: International Nonproprietary Name: Vorapaxar indications: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease innovator: Merck (Zontivity) Country Coverage: Australia Canada France Germany ...

Jan, 2015
Voglibose - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot saves you days of research and instantly ... Name: Voglibose indications: Lowering post-prandial blood glucose levels in people with diabetes mellitus innovator: Mascot Health (Voglib) Country Coverage ...

Jan, 2015
Vilanterol - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... : Vilanterol indications: Maintenance bronchodilator treatment to relieve symptoms of chronic obstructive pulmonary disease, in combination with Umeclidinium bromide; Treatment of asthma in combination with Fluticasone furoate; Maintenance treatment of airflow obstruction and for reducing exacerbations in ...

Jan, 2015
Vemurafenib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... , save searches and results This report covers: International Nonproprietary Name: Vemurafenib indications: Treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma innovator: Roche (Zelboraf) Country Coverage: Australia Canada France Germany Great Britain Italy Japan ...

Jan, 2015
Umeclidinium bromide, Vilanterol - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... This report covers: International Nonproprietary Name: Umeclidinium bromide, Vilanterol indications: Maintenance bronchodilator treatment to relieve symptoms of chronic obstructive pulmonary disease innovator: GlaxoSmithKline (Anoro Ellipta, Laventair) Country Coverage: Australia Canada France ...

Jan, 2015
Umeclidinium bromide - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Umeclidinium bromide indications: Maintenance treatment to relieve symptoms of chronic obstructive pulmonary disease innovator: GlaxoSmithKline (Incruse, Incruse Ellipta) Country Coverage: Australia Canada France Germany Great ...

Jan, 2015
Tofacitinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Tofacitinib indications: Treatment of psoriasis; Treatment of rheumatoid arthritis optionally in combination with Methotrexate innovator: Pfizer (Xeljanz) Country Coverage: Australia Canada France Germany Great Britain Italy ...

Jan, 2015
Telithromycin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... spectrum of Telithromycin; Treatment of acute exacerbation of chronic bronchitis; Treatment of acute sinusitis; Treatment of tonsillitis or pharyngitis caused by streptococcus pyogenes, as an alternative when beta lactam antibiotics are not appropriate in countries/regions with a significant prevalence of ...

Jan, 2015
Telaprevir - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results This report covers: International Nonproprietary Name: Telaprevir indications: Treatment of chronic hepatitis C genotype 1 infection in combination with Peginterferon alfa and Ribavirin innovator: Vertex Pharm (Incivek); Janssen (Incivo) Country Coverage: Australia Canada France Germany ...

Jan, 2015
Teduglutide - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... Add your own notes, save searches and results This report covers: International Nonproprietary Name: Teduglutide indications: Treatment of short bowel syndrome innovator: NPS Pharma (Revestive, Gattex) Country Coverage: Australia Canada France Germany Great Britain Italy Japan Spain USA ...

Jan, 2015
Tedizolid - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source of ... Nonproprietary Name: Tedizolid indications: Treatment of acute bacterial skin and skin structure infections innovator: Cubist Pharm (Sivextro) Country Coverage: Australia ...

Jan, 2015
Tasimelteon - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... own notes, save searches and results This report covers: International Nonproprietary Name: Tasimelteon indications: Treatment of non-24-hour sleep-wake disorder innovator: Vanda Pharm (Hetlioz) Country Coverage: Australia Canada France Germany Great Britain Italy Japan Spain USA Please ...

Jan, 2015
Tafluprost - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Tafluprost indications: Reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension, optionally as adjunctive therapy to beta blockers innovator: Santen (Taflotan, Tapros); Merck (Saflutan, Zioptan) ...

Jan, 2015
Ruxolitinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results This report covers: International Nonproprietary Name: Ruxolitinib indications: Treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF innovator: Incyte (Jakafi); Novartis (Jakavi) Country Coverage: ...

Jan, 2015
Rufinamide - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... , save searches and results This report covers: International Nonproprietary Name: Rufinamide indications: Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome innovator: Eisai (Banzel, Inovelon) Country Coverage: Australia Canada France Germany Great Britain Italy Japan ...

Jan, 2015
Roflumilast - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Roflumilast indications: Treatment and maintenance of severe chronic obstructive pulmonary disease, optionally in combination with bronchodilators and/or corticosteroids innovator: Nycomed (Daxas, Libertek); Merck (Daxas); Forest Res ( ...

Jan, 2015
Rilpivirine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results This report covers: International Nonproprietary Name: Rilpivirine indications: Treatment of HIV-1 in combination with Ritonavir and other antiretroviral agents innovator: Tibotec (Edurant); Gilead (Eviplera); Janssen (Edurant) Country Coverage: Australia Canada France Germany Great ...

Jan, 2015
Retigabine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... , save searches and results This report covers: International Nonproprietary Name: Retigabine indications: Adjunctive treatment of partial onset seizures innovator: Glaxosmithkline (Trobalt); Valeant (Potiga) Country Coverage: Australia Canada France Germany Great Britain Italy Japan Spain ...

Jan, 2015
Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source ... Name: Repaglinide indications: Treatment of type 2 diabetes mellitus innovator: Novo Nordisk (Prandin, NovoNorm, GlucoNorm, Prandimet); Daiichi Sankyo (Prandin) Country Coverage ...

Jan, 2015
Ranelic acid - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... : International Nonproprietary Name: Ranelic acid indications: Treatment of postmenopausal osteoporosis to reduce the risk of fractures, optionally in combination with Vitamin D and/or Calcium innovator: Servier (Protos, Osseor, Protelos) Country Coverage: Australia Canada France Germany Great ...

Jan, 2015
Quetiapine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... Nonproprietary Name: Quetiapine indications: Treatment of schizophrenia; Treatment of depressive episodes associated with bipolar disorder; Treatment or prevention of relapse/recurrence of manic, depressive or mixed episodes of bipolar disorder or of acute mania associated with bipolar disorder, as ...

Jan, 2015
Ponatinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source of patent ... or blast phase chronic myeloid leukaemia or Philadelphia chromosome positive acute lymphoblastic leukaemia in patients with T315I mutation or no other tyrosine kinase therapy ...

Jan, 2015
Ospemifene - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... your own notes, save searches and results This report covers: International Nonproprietary Name: Ospemifene indications: Treatment of moderate to severe dyspareunia innovator: Shionogi (Osphena) Country Coverage: Australia Canada France Germany Great Britain Italy Japan Spain USA Please ...

Jan, 2015
Ocriplasmin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... , save searches and results This report covers: International Nonproprietary Name: Ocriplasmin indications: Treatment of symptomatic vitreomacular adhesion innovator: ThromboGenics (Ocriplasmin); Alcon (Ocriplasmin) Country Coverage: Australia Canada France Germany Great Britain Italy Japan ...

Jan, 2015
Nelarabine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... notes, save searches and results This report covers: International Nonproprietary Name: Nelarabine indications: Treatment of acute lymphoblastic leukaemia innovator: GlaxoSmithKline (Arranon, Atriance) Country Coverage: Australia Canada France Germany Great Britain Italy Japan Spain USA ...

Jan, 2015
Metformin, Vildagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... This report covers: International Nonproprietary Name: Metformin, Vildagliptin indications: Treatment of type 2 diabetes mellitus, optionally in combination with a sulphonylurea or Insulin innovator: Novartis (Galvumet, Sobrea, Eucreas, Icandra, Zomarist) Country Coverage: Australia Canada France ...

Jan, 2015
Metformin, Sitagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Metformin, Sitagliptin indications: Improvement of glycemic control in patients with type 2 diabetes mellitus, optionally in combination with a PPARy agonist innovator: Merck (Janumet, Velmetia, Efficib, Ristfor) Country Coverage: ...

Jan, 2015
Metformin, Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source of patent ... : Metformin, Repaglinide indications: Adjunctive treatment to diet and exercise for improving glycaemic control in patients with type 2 diabetes mellitus innovator: Novo ...

Jan, 2015
Metformin, Dapagliflozin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source of ... : Metformin, Dapagliflozin indications: Adjunctive treatment to diet and exercise for improving glycaemic control innovator: AstraZeneca (Xigduo); Bristol Myers Squibb (Xigduo) ...

Jan, 2015
Metformin, Canagliflozin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results This report covers: International Nonproprietary Name: Metformin, Canagliflozin indications: Adjunctive therapy to diet and exercise to improve glycaemic control in patients with type 2 diabetes innovator: Janssen (Invokamet, Vokanamet) Country Coverage: Australia Canada France Germany ...

Jan, 2015
Meropenem - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... This report covers: International Nonproprietary Name: Meropenem indications: Treatment of hospital acquired lower respiratory tract infection; Treatment of nosocomial pneumonia; Treatment of complicated urinary tract infection; Treatment of complicated skin and skin structure infections; Treatment of ...

Jan, 2015
Memantine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... own notes, save searches and results This report covers: International Nonproprietary Name: Memantine indications: Treatment of Alzheimer's disease innovator: Forest Labs (Namenda); Lundbeck (Ebixa) Country Coverage: Australia Canada France Germany Great Britain Italy Japan Spain USA ...

Jan, 2015
Maraviroc - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... save searches and results This report covers: International Nonproprietary Name: Maraviroc indications: Treatment of CCR5-tropic HIV in combination with other antiretroviral agents innovator: Pfizer (Celsentri, Selzentry) Country Coverage: Australia Canada France Germany Great Britain Italy ...

Jan, 2015
Macitentan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... This report covers: International Nonproprietary Name: Macitentan indications: Treatment of pulmonary arterial hypertension, optionally in combination with approved PAH treatments, including phosphodiesterase-5 inhibitors or inhaled prostanoids innovator: Actelion (Opsumit) Country Coverage: Australia ...

Jan, 2015
Lercanidipine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Lercanidipine indications: Treatment of hypertension, optionally in combination with Felodipine or thiazide diuretics innovator: Napp (Zanidip); Solvay (Zanidip, Zan-Extra); Recordati (Zanidip) Country Coverage: Australia Canada ...

Jan, 2015
Ketorolac, Phenylephrine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Ketorolac, Phenylephrine indications: Maintenance of pupil size by preventing intraoperative miosis and reducing postoperative ocular pain innovator: Omeros (Omidria) Country Coverage: Australia Canada France Germany Great ...

Jan, 2015
Ivacaftor - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results This report covers: International Nonproprietary Name: Ivacaftor indications: Treatment of cystic fibrosis in patients having a G551D mutation in the cystic fibrosis transmembrane conductance regulator gene innovator: Vertex (Kalydeco) Country Coverage: Australia Canada France Germany ...

Jan, 2015
Ivabradine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... , biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot saves you days of research and instantly ... : Treatment of chronic stable angina in coronary artery disease patients with normal sinus rhythm, optionally in combination with beta blockers, preferably Atenolol ...

Jan, 2015
Hydrochlorothiazide, Losartan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... own notes, save searches and results This report covers: International Nonproprietary Name: Hydrochlorothiazide, Losartan indications: Treatment of hypertension innovator: Merck (Hyzaar, CozaarComp) Country Coverage: Australia Canada France Germany Great Britain Italy Japan Spain USA ...

Jan, 2015
Glimepiride, Pioglitazone - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... Adjunct to diet, exercise and weight loss, to lower the blood glucose, reduce insulin resistance and improve glycaemic control in patients with non-insulin-dependent (type 2) diabetes mellitus innovator: Takeda (Duetact, Tandemact) Country Coverage: Australia Canada France ...

Jan, 2015
Fluticasone, Vilanterol - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... indications: Treatment of airflow obstruction in chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema; Reduce exacerbations of chronic obstructive pulmonary disease in patients with a history of exacerbations; Treatment of asthma in patients 12 years and older innovator: ...

Jan, 2015
Fluralaner - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source ... Name: Fluralaner indications: Treatment and prevention of flea infestations in dogs; Treatment and control of tick infestations in dogs innovator: Intervet (Bravecto) Country ...

Jan, 2015
Ezetimibe, Simvastatin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Ezetimibe, Simvastatin indications: Treatment of homozygous familial hypercholesterolaemia; Adjunctive therapy to diet in the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia ...

Jan, 2015
Ezetimibe, Rosuvastatin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... searches and results This report covers: International Nonproprietary Name: Ezetimibe, Rosuvastatin indications: Adjunctive therapy to diet for treatment of primary hypercholesterolemia innovator: Merck (Rosuzet, Ezalo) Country Coverage: Australia Canada France Germany Great Britain Italy ...

Jan, 2015
Etravirine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Etravirine indications: Treatment of HIV-1, optionally in combination with antiretroviral agents innovator: Janssen (Intelence); Tibotec (Intelence) Country Coverage: Australia Canada France Germany Great Britain Italy Japan ...

Jan, 2015
1 2 3 4 5 >
Skip to top